India · Delayed Price · Currency is INR Indoco Remedies Earnings Call Transcripts
Fiscal Year 2026
-
Q4 saw a strong turnaround with 25.8% YoY standalone revenue growth, led by international formulations, while domestic sales were muted due to seasonality. Debt remains high but is being managed, and no major CapEx is planned. Receivables and forex losses impacted financials.
-
Q3 FY26 saw strong export and API growth, improved subsidiary performance, and margin expansion, despite flat domestic sales and non-recurring costs from regulatory issues. Debt reduction and margin improvement are key priorities, with robust growth expected in Europe, OTC, and API segments.
-
Q2 FY26 saw strong revenue growth and margin recovery, driven by robust India and emerging market performance, new product launches, and operational improvements. USFDA remediation and subsidiary losses remain key risks, but management expects further growth, margin expansion, and limited CapEx ahead.
-
Q1 FY26 saw sequential revenue and EBITDA improvement, driven by OTC and emerging markets, despite ongoing FDA remediation and flat domestic formulations. Debt reduction and cost control efforts continue, with all plants expected fully operational by Q3.
Fiscal Year 2025
-
FY25 saw significant operational and financial challenges, with revenues and margins declining due to regulatory setbacks and high investment in OTC and manufacturing upgrades. Recovery is expected from Q2 as remediation completes and international supplies resume, with margin improvement and growth in both domestic and OTC segments anticipated.
-
Q3 FY25 saw a sharp revenue and margin decline due to supply disruptions from regulatory and operational challenges, especially in the US and EU. Domestic business remained strong, with robust prescription growth and new launches. Remediation costs and regulatory risks will persist for at least two more quarters.
-
Q2 FY25 saw muted revenue growth and margin compression due to plant upgrades and FDA remediation, impacting international sales, especially in the US. Domestic business grew modestly, while major CapEx was incurred for capacity expansion. Recovery is expected from Q4 as upgrades complete.
-
Q1 FY25 saw modest revenue decline and margin compression due to US supply constraints and product mix, but strong growth in key brands and new launches. Remediation and CapEx initiatives are expected to drive margin recovery and robust growth in US, Europe, and emerging markets from Q3 onward.